# Ace Vision Group

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ace-vision-group

- Industry: Healthcare Specialists
- Headquarters: Boston, US
- Website: www.acevisiongroup.com
- Total disclosed funding: $14M
- Latest round: Series B (Dec 28, 2021)
- Investors on record: 1

## About

Ace Vision Group, Inc. is a US-based company focusing on innovative ophthalmic laser therapies aimed at addressing age-related vision issues, particularly presbyopia, through advanced laser technology.Founded in 2006 in Boston, US, Ace Vision Group, Inc. specializes in ophthalmic laser devices. The company has undergone strategic pivots to enhance its product offerings and currently operates independently. AnnMarie Hipsley serves as the CEO and has a history of involvement in the healthcare sector. The firm has raised a total of USD 29.4 mn, including USD 29.4 mn during its Series B funding round completed on April 24, 2025.Ace Vision Group, Inc. specializes in innovative ophthalmic laser devices, with its core product being the Laser Scleral Microporation (LSM) therapy. This touchless eye laser therapy targets presbyopia, affecting over 2.1 billion people globally, by providing a microporation therapeutic approach to rejuvenate the aging eye. The LSM treatment is currently in clinical trials in select international markets, indicating a focus on expanding its reach in the eye care sector.The revenue model of Ace Vision Group centers on partnerships with eye care providers, allowing the integration of their LSM therapy into clinical practices. The company engages in direct transactions with healthcare facilities, offering LSM treatment as a specialized service for patients with age-related vision loss. Ace Vision Group utilizes a direct-to-provider approach to generate revenue from its ophthalmic solutions and services.In April 2025, Ace Vision Group, Inc. raised USD 29.4 million in Series B funding. This funding will support the development of its Gen II VisioLite® Ophthalmic Laser. The company is also focused on expanding its presence in international markets where it has initiated clinical trials for its LSM therapy, aiming to launch new products aligned with its strategic growth plans.

## Funding rounds

- Series B, Dec 28, 2021, $14M — Picerne Group

## Investors

- Picerne Group (https://capitalatlas.ai/funds/picerne-group) — Series B